The promising results obtained by the first phase I trial investigating revumenib have prompted the design of new clinical trials with different molecules and drug combinations, possibly mimicking the path of other successful predecessors among smart drugs, such as all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia [59] and FLT3 inhibitors for FLT3 mutant AML [60], leading to a change in the paradigms of the treatment and prognosis of the disease. Here, FLT3 is linked to acute promyelocytic leukemia.